Pharmacokinetics of Telavancin in Normal and Obese Subjects
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize plasma and urinary concentrations of telavancin
following intravenous administration of a single dose of telavancin in healthy subjects who
are normal weight, overweight, and obese.
Phase:
Phase 1
Details
Lead Sponsor:
University of Illinois at Chicago
Collaborators:
Theravance Biopharma Theravance Biopharma Antibiotics, Inc.